GSA Capital Partners LLP Has $2.12 Million Position in Catalent Inc (CTLT)
GSA Capital Partners LLP increased its stake in Catalent Inc (NYSE:CTLT) by 59.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 52,972 shares of the company’s stock after purchasing an additional 19,661 shares during the quarter. GSA Capital Partners LLP’s holdings in Catalent were worth $2,115,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of CTLT. BlackRock Inc. increased its position in Catalent by 15.2% in the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after buying an additional 2,316,849 shares during the period. Vanguard Group Inc. increased its position in Catalent by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock worth $355,192,000 after buying an additional 369,526 shares during the period. Janus Henderson Group PLC bought a new position in Catalent in the 2nd quarter worth approximately $239,629,000. JPMorgan Chase & Co. increased its position in Catalent by 4.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,139,690 shares of the company’s stock worth $180,403,000 after buying an additional 226,705 shares during the period. Finally, State Street Corp increased its position in Catalent by 10.7% in the 2nd quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after buying an additional 418,196 shares during the period. Hedge funds and other institutional investors own 99.49% of the company’s stock.
Shares of Catalent Inc (NYSE:CTLT) opened at $41.12 on Friday. Catalent Inc has a 1 year low of $25.51 and a 1 year high of $43.39. The firm has a market capitalization of $5,322.35, a price-to-earnings ratio of 28.01, a price-to-earnings-growth ratio of 2.57 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49.
A number of analysts have recently issued reports on the company. Royal Bank of Canada assumed coverage on Catalent in a research report on Wednesday. They set an “outperform” rating and a $46.00 price objective on the stock. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. BidaskClub cut Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Piper Jaffray Companies boosted their price objective on Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, November 7th. Finally, Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $48.00 price objective on the stock in a research report on Monday, November 6th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $44.44.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction on Tuesday, November 21st. The shares were bought at an average price of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/gsa-capital-partners-llp-has-2-12-million-position-in-catalent-inc-ctlt/1767496.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.